Contributing Member of the Healthcare Councils

GLG News by this Author

Gambling for surgery abroad - cheap option?

August 20, 2007

Analysis of:Shire's New ADHD medication, VYVANSE(TM) (lisdexamfetamine dimesylate) Now Available in U.S. Pharmacies Nationwide | www.eurekalert.org

The special report published in the 'Medpage Today' (August 13, 2007), has introduced a new concept, 'medical tourism', mainly to emphasize the cheap option for surgery, prompting US patients to travel as far as India, Thailand, Singapore, due to reasons that many Americans cannot afford it in the USA!

Priority Review for ABILIFY(R) (aripiprazole) as adjunctive to antidepressant therapy (ADT)

August 20, 2007

Analysis of:ABILIFY(R) (aripiprazole) Supplemental New Drug Application Receives Priority Review by U.S. Food And Drug Administration for Adjunctive Treatment in Adults With Major Depressive Disorder | www.pipelinereview.com

This news will be an addedd benefit to the treatment of major depressive disorder. This article is designed carerfully to draw attention to three main areas of this drug - priorty review procedure by the FDA and possible outcomes, accompanying antidepressant therapy (ADT), safety information on Abilify, and types of Abilfy for each type of depressive disorder.  The news is published in the PipelineReview.com. 

Nationwide availability of Shire's new ADHD medication -VYVANSE (lisdexamfetamine dimesylate)

August 20, 2007

Analysis of:Shire's New ADHD medication, VYVANSE(TM) (lisdexamfetamine dimesylate) Now Available in U.S. Pharmacies Nationwide | www.eurekalert.org

Published in the PRNewswire-FirstCall, this news may enlighten the medical practice for getting another new drug, VYVANSE (lisdexamfetamine dimesylate), to treat ADHD. This news is useful to patients as well, for highlighting the benefits of intake with reports from a case study, and safety information.

Vasomotor symptoms associated with menopause-approval from the FDA

August 17, 2007

Analysis of:Wyeth Receives Approvable Letter from FDA for PRISTIQ for the Treatment of Vasomotor Symptoms Associated with Menopause | www.pipelinereview.com

This news published in the Pipeline Review should generate interests about the development of drugs to treat moderate to severe vasomotor symptoms. PRISTIQ(TM) (desvenlafaxine), a serotonin-norepinephrine reuptake inhibitor (SNRI),is still under further development as the article suggests, and Wyeth Pharmaceuticals responsible to market the drug is confirming the commitment to provide additional data to satisfy the FDA review process.

News watch - Imclone Systems New Appointment

August 14, 2007

Analysis of:Industry Fights Switch to Generics for Epilepsy | online.wsj.com

This news published in the PipelineReview.com is important for publicising the leadership for this company, embracing cancer treatment research with patients' needs.

Campaign against switching to inexpensive generics epilepsy pills

July 27, 2007

Analysis of:Industry Fights Switch to Generics for Epilepsy | online.wsj.com

The free preview published in the 'The Wall Street Journal' draws attention to the campaign by the Epilepsy foundation for a bill to discourage pharmacists to persuade patients to opt for inexpensive generic epilepsy pills. The news will benefit patients for being informed about the side-effects of generic epilepsy pills. However, the issue of popularizing the drugs from the pharmacists' perspectives need to be evaluated appropriately, especially when the trend will be to go for inexpensive drugs than expensive ones for patients with financial constraints. 

Alternative treatment to depression: where we go from here?

July 26, 2007

Analysis of:The Unmedicated Mind: Backlash against antidepressants is fueling new interest in alternative treatments | online.wsj.com

The article reports the benefits of alternative treatment to depression, particularly, the emotional freedom technique, craniosacral therapy, naturopath, chiropractors, acupuncture and even fish oil treatment!  It is an interesting article with a good prospect of further research in this area

Frequency of bupropion use for the treatment of depression: a research report

July 16, 2007

Analysis of:Once-daily Wellbutrin XL | www.ncbi.nlm.nih.gov

This research reports findings from a longitudinal cohort comparing different points in bupropion use in a day (once daily with bupropion extended-release versus twice daily with bupropion sustained-release). It is neither an innovative approach nor a new drug release, hence the appeal is for the sustained drug use and drug management sectors.

INTUNIV extended release tablets for the treatment of ADHD

July 16, 2007

Analysis of:Shire Receives Approvable Letter from FDA for INTUNIV(TM) (guanfacine) Extended Release, a Nonstimulant for the Treatment of ADHD | www.pipelinereview.com

This article is providing a significant development in treating ADHD with the disclosure of U.S Food and Drug administration approval for INTUNIV extended release tablets. The news shows that this treatment is not leading  to drug dependency and drug abuse due to its nonstimulant's feature. Shire plc responsible for this development in ADHD treatment is furthermore confirming the clinical efficacy of this drug and a treatment replacement option for the existing ADHD drugs.

Exelon skin patch is a new treatment for Alzhiemer's disease-Novartis wins the US food and drug administration approval

July 16, 2007

Analysis of:UPDATE: Novartis Wins FDA OK For Alzheimer's Drug Patch | money.cnn.com

This article is definitely a breaking news for the treatment of Alzhiember's disease. In contrast to traditional oral capsule, the use of skin patch will show good practice in patient's care in which severe cognitive decline is dealt with simple and effective therapeutic technique. The news is also disclosing patient's choice in treatment for Alzhiemer's disease, and a simple, effective and innovative alternative to oral drug use to treat this disease.

Intervention techniques to improve chronic disease management quality can yield better quality care delivery.

July 2, 2007

Analysis of:Chronic Disease Management Quality Improvement Efforts Yield Better Care Delivery | www.medicalnewstoday.com

Intervention techniques to improve chronic disease management quality could be useful to improve quality care delivery for chronic disease, especially for deprived and disadvantaged population groups living in the inner city areas in the USA. This article reports a study, published in the March 1 New England Journal of Medicine, focuses on the principle quality improvement efforts adopted by HRSA for 1,000 health centers nationally, the Health Disparities Collaboratives. The article is important for showing significant insights into the intervention strategies for improving disease management quality with an aim to improve care delivery. 

Employer's initiatives to introduce health coaching: a debate between remote type vs face-to-face coaching

July 2, 2007

Analysis of:Employers' plans emphasize wellness | www.pennlive.com

Employer's attention to wellness coaching is the most recent pragmatic step to ensure employee's health and wellbeing. This article has captured the modern client-focused approach taken by employer's to offer wellness coaching programme to employees. This shows the employer's awareness to use a modern cost-effective health coaching programme on the cutting edge of modern technology.

Previous Page : 123456101 to 112 of 112